Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05761743 · ClinicalTrials.gov registry record

Glycemic Control, Type II Diabetes, Parathyroidectomy

A clinical trial of Type 2 Diabetes and Primary Hyperparathyroidism, sponsored by The Cleveland Clinic.

Active
Registry status
80
Enrollment target
1
Study location

NCT05761743 is a study of Type 2 Diabetes and Primary Hyperparathyroidism that is active but no longer recruiting, run by The Cleveland Clinic. The registered enrollment target is 80 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05761743, a study of Type 2 Diabetes and Primary Hyperparathyroidism, is active but no longer recruiting, sponsored by The Cleveland Clinic.

ACTIVE NOT RECRUITING
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess glycemic control after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus.

Interventions

  • DIAGNOSTIC_TEST Urine and Blood Test

Study Locations (1)

Ohio

  • Cleveland Clinic Main Campus - Cleveland

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-02-27
Est. Completion 2026-02-01

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT05761743

The ClinicalTrials.gov registry entry for NCT05761743 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (93% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Urine and Blood Test is the first listed.

NCT05761743 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05761743 about?

NCT05761743 is a clinical study titled "Glycemic Control, Type II Diabetes, Parathyroidectomy". The purpose of this study is to assess glycemic control after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus.

What is the current status of trial NCT05761743?

This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2023-02-27. Estimated completion is 2026-02-01.

What conditions does trial NCT05761743 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Primary Hyperparathyroidism.

What interventions are being tested in trial NCT05761743?

The interventions under investigation include: Urine and Blood Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05761743?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05761743 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.